Loading…
Loading…
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is up 8% to $147.37 in Friday morning trading, a sharp single-name move on a session when biotech as a group is quiet and broader U.S. equities are only modestly higher.
Amundi lowered its stake in Moderna, Inc. (NASDAQ: MRNA) by 1.8% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 888,779 shares of the company's stock after selling 16,044 shares during the period. Amundi owned 0.22% of Moderna worth
Retail investors often monitor the trading activity of members of Congress. Investors may want to pay particular attention to recent trades from one member, with stocks connected to Elon Musk and Warren Buffett among the bets.
Amgen delivers strong profitability and a diverse portfolio of established chronic disease treatments. Moderna continues to transition its business as it pivots from pandemic products to a broader mRNA pipeline.
If AI and robotics suddenly feel like they are moving faster, August gave investors plenty of evidence that the pace really is accelerating. We saw longer-running agents, faster and cheaper inference, AI systems reaching into laboratories and physical equipment, robots learning from fewer demonstrations, and new capital and infrastructure forming around commercial deployment.
IHE's concentrated pharma holdings delivered 50% returns over one year, while RSPH's equal-weight healthcare approach generated 29%. Risk profiles differ sharply too.
Moderna stock surges 143% in a month on positive cancer therapy results, but competition and valuation raise key questions for investors.
Nykredit A S purchased a new position in Moderna, Inc. (NASDAQ: MRNA) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 13,042 shares of the company's stock, valued at approximately $913,000. A number of other institutional investors have also recently added